Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	1258-84-0
Formula :	C₃₀H₄₀O₄
M.W :	464.64
SMILES Code :	C[C@@]12[C@](C)([C@]3([C@@](C)(CC1)CC[C@](C(OC)=O)(C)C3)[H])CC[C@]4(C)C2=CC=C5C4=CC(=O)C(O)=C5C
Synonyms :	Celastrol methyl ester; NSC 99281; UNII-28ZK7PR57S
English Name :	Methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate
MDL No. :	MFCD01711331

GHS Pictogram:
Signal Word:
Hazard Statements:
Precautionary Statements:
Class:
UN#:
Packing Group:

HTR-8/SVneo cells	0.25-4 µM	24 hours	Inhibited trophoblast cell proliferation	Drug Des Devel Ther. 2020 Nov 2;14:4659-4670
KBM5-T315I cells	135 nM (IC50)	72 hours	Inhibited growth and induced apoptosis	Mol Cancer. 2010 May 19;9:112
HTR-8/SVneo cells	0.5 µM	24 hours	Induced trophoblast cell apoptosis	Drug Des Devel Ther. 2020 Nov 2;14:4659-4670
HTR-8/SVneo cells	0.5 µM	24 hours	Inhibited trophoblast cell migration	Drug Des Devel Ther. 2020 Nov 2;14:4659-4670
KBM5 cells	199 nM (IC50)	72 hours	Inhibited growth and induced apoptosis	Mol Cancer. 2010 May 19;9:112
Panc-1 cells	0.625 to 5 µM	72 hours	Inhibited cell proliferation and induced apoptosis	Int J Oncol. 2014 May;44(5):1707-15.
Bone marrow-derived macrophages (BMMs)	75 nM	1, 3, 5 days	To determine the stage at which Pristimerin inhibits osteoclast formation, results showed that Pristimerin inhibited osteoclast formation at the early stage (1-3 days).	Front Pharmacol. 2021 Jan 15;11:621110
Bone marrow-derived macrophages (BMMs)	100 nM	1, 3, 5 days	To evaluate the effect of Pri on osteoclast-related gene expression, results showed Pri significantly downregulated the expression of TRAP, CTSK, c-Fos, NFATc1, DC-STAMP, and V-ATPase d2	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
Bone marrow-derived macrophages (BMMs)	0, 25, 50, 100 nM	10 days	To evaluate the effect of Pri on bone resorption function, results showed Pri significantly reduced the bone resorption ability of osteoclasts	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
Rat Brain Astrocytes (RBA-1)	0.1, 0.3, 0.5 µM	12 and 24 hours	Pristimerin inhibited LPS-induced MMP-9 expression and cell migration through attenuating NOX/ROS-dependent NF-κB activation.	J Inflamm Res. 2020 Jul 20;13:325-341
MDA-MB-231 cells	0.1, 0.2, 0.5, 1 mM	14 days	Pristimerin significantly inhibited the colony formation ability of MDA-MB-231 cells.	Biomed J. 2021 Dec;44(6 Suppl 1):S84-S92
BV2 cells	10 µM	15 minutes	To evaluate the inhibitory effect of Pristimerin on 2-AG hydrolysis. Results showed that 10 μM Pristimerin inhibited [3H]-2-OG hydrolysis by 25%.	Br J Pharmacol. 2012 Dec;167(8):1596-608
Mouse chondrocytes	50 nM, 100 nM, 200 nM	24 and 48 hours	To assess the effect of Pristimerin on chondrocyte viability, results showed no apparent effect on cell viability at concentrations below 400 nmol	Drug Des Devel Ther. 2024 Nov 27;18:5445-5459
Human brain vascular pericytes (HBVPs)	125, 250, 500 nM	24 hours	To evaluate the inhibitory effect of Pristimerin on Shh-induced pericyte adhesion and migration	Cell Death Dis. 2020 Apr 14;11(4):232
NCI-H446 cells	0.25 µM	24 hours	Inhibited cell proliferation, induced G0/G1 arrest and cell apoptosis	Int J Mol Med. 2019 Mar;43(3):1382-1394
A549 cells	0.25 µM	24 hours	Inhibited cell proliferation, induced G0/G1 arrest and cell apoptosis	Int J Mol Med. 2019 Mar;43(3):1382-1394
D-407 cells	30 µM	24 hours	D-407 cells showed higher resistance to the cytotoxic effect of Pristimerin, displaying only 20% cytotoxicity upon treatment with 30 µM Pristimerin.	J Cell Mol Med. 2020 Jun;24(11):6208-6219
RGC-5 cells	30 µM	24 hours	RGC-5 cells showed higher resistance to the cytotoxic effect of Pristimerin, displaying only 20% cytotoxicity upon treatment with 30 µM Pristimerin.	J Cell Mol Med. 2020 Jun;24(11):6208-6219
UM-1 cells	1-30 µM	24 hours	Pristimerin inhibited UM-1 cell viability in a dose-dependent manner, reaching 80% cell death at 30 µM. Moreover, Pristimerin inhibited the migration and invasion of UM-1 cells, caused a rapid increase of ROS, decreased mitochondrial membrane potential, induced the accumulation of cells in G0/G1 phase, ending with apoptotic cell death.	J Cell Mol Med. 2020 Jun;24(11):6208-6219
Human uveal melanoma cells (UM cells)	1 µM	24 hours	To assess the effect of PRI on UM cell cycle distribution, results showed that PRI induced G1 phase accumulation and reduced G2 phase accumulation.	J Cell Mol Med. 2019 Nov;23(11):7545-7553
Human uveal melanoma cells (UM cells)	0-10 µM	24 hours	To evaluate the inhibitory effect of PRI on UM cell proliferation, results showed that PRI inhibited cell proliferation in a dose-dependent manner.	J Cell Mol Med. 2019 Nov;23(11):7545-7553
MDA-MB-231 cells	0.1, 0.2, 0.3 mM	24 hours	Pristimerin significantly reduced the numbers of invasion and adhesion of MDA-MB-231 cells, and its inhibitory effects were dose-dependent.	Biomed J. 2021 Dec;44(6 Suppl 1):S84-S92
Lymph node cells (LNC)	0.1/0.3 µM	24 hours	To test the effect of Pristimerin on transcription factors STAT3 and ROR-γt. Results showed Pristimerin reduced the expression of ROR-γt and pSTAT3.	Oncol Rep. 2015 Jul;34(1):518-24
GL261 cells	0, 0.25, 0.5, 1, 2 µM	24 hours	To evaluate the effect of Pristimerin on GL261 cell viability. Results showed that Pristimerin at 0.25 μM severely inhibited GL261 cell viability.	Biosci Rep. 2019 May 14;39(5):BSR20182389
U373 cells	0, 0.25, 0.5, 1, 2 µM	24 hours	To evaluate the effect of Pristimerin on U373 cell viability. Results showed that Pristimerin at 0-1 μM did not significantly affect U373 cell viability, but at 2 μM, it remarkably inhibited cell proliferation.	Biosci Rep. 2019 May 14;39(5):BSR20182389
Mouse chondrocytes	50 nM, 100 nM, 200 nM	24 hours	To assess the effect of Pristimerin on ECM degradation, results showed Pristimerin could concentration-dependently reverse IL-1β-induced ECM degradation	Drug Des Devel Ther. 2024 Nov 27;18:5445-5459
Mouse chondrocytes	50 nM, 100 nM, 200 nM	24 hours	To assess the effect of Pristimerin on IL-1β-induced inflammatory factor expression, results showed Pristimerin could partially reverse the upregulation of inflammatory factors induced by IL-1β	Drug Des Devel Ther. 2024 Nov 27;18:5445-5459
Lymph node cells (LNC)	0.1/0.3 µM	24 hours	To test the effect of Pristimerin on transcription factors STAT3 and ROR-γt. Results showed Pristimerin reduced the expression of ROR-γt and pSTAT3.	Clin Immunol. 2014 Dec;155(2):220-30
Human umbilical vascular endothelial cells (HUVECs)	0.5 µM, 1 µM, 2 µM	24 hours (proliferation assay), 8 hours (migration assay), 6 hours (tube formation assay)	Pristimerin inhibited VEGF-induced HUVECs proliferation, migration, and tube formation in a concentration-dependent manner. 0.5 μM significantly inhibited proliferation, 1 μM significantly inhibited migration, and 0.5 μM significantly inhibited tube formation.	Molecules. 2012 Jun 5;17(6):6854-68
Bone marrow-derived macrophages (BMMs)	0, 10, 25, 50, 75 nM	3 days	To evaluate the effect of Pristimerin on osteoclast function, results showed that Pristimerin significantly inhibited bone resorption and actin ring formation.	Front Pharmacol. 2021 Jan 15;11:621110
Bone-marrow dendritic cells (BMDCs)	0.1-0.4 µM	30 min	Inhibited caspase-1 activation and IL-1β secretion	Acta Pharmacol Sin. 2021 Jun;42(6):975-986
Mouse peritoneal macrophages	0.1-0.4 µM	30 min	Inhibited caspase-1 activation and IL-1β secretion	Acta Pharmacol Sin. 2021 Jun;42(6):975-986
Bone-marrow-derived macrophages (BMDMs)	0.1-0.4 µM	30 min	Inhibited caspase-1 activation and IL-1β maturation	Acta Pharmacol Sin. 2021 Jun;42(6):975-986
Bacillus subtilis	10 µg/mL	30 minutes	Evaluation of the antimicrobial activity of Pristimerin against B. subtilis, showing weaker inhibitory effects on DNA and RNA synthesis.	Foods. 2021 Mar 11;10(3):591
Human uveal melanoma cells (UM cells)	0.1-3 µM	40 minutes	To evaluate the effect of PRI on IGF-1-induced IGF-1R and its downstream signaling pathways, results showed that PRI inhibited the phosphorylation of IGF-1R and its downstream pathways in a dose-dependent manner.	J Cell Mol Med. 2019 Nov;23(11):7545-7553
Human microvascular endothelial cell line (HMEC-1)	125, 250, 500 nM	48 hours	To evaluate the inhibitory effect of Pristimerin on Shh-induced endothelial cell proliferation	Cell Death Dis. 2020 Apr 14;11(4):232
Human umbilical vein endothelial cells (HUVEC)	125, 250, 500 nM	48 hours	To evaluate the inhibitory effect of Pristimerin on Shh-induced endothelial cell proliferation	Cell Death Dis. 2020 Apr 14;11(4):232
A549 cells	1.91 µM (IC50)	48 hours	Evaluate the synergistic inhibitory effects of Pristimerin and paclitaxel on the viability of A549 cells, results showed that Pristimerin significantly enhanced the chemosensitivity of paclitaxel	Nano Converg. 2022 Nov 24;9(1):52
MDA-MB-231 cells	0.1, 0.2, 0.5, 1 mM	48 hours	Pristimerin significantly inhibited cell proliferation, and its inhibitory effect was dose-dependent.	Biomed J. 2021 Dec;44(6 Suppl 1):S84-S92
Bone marrow-derived macrophages (BMMs)	0, 25, 50, 100 nM	48 or 96 hours	To evaluate the effect of Pri on BMMs cell viability, results showed no significant effect on cell viability at concentrations below 100 nM	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
Bone marrow-derived macrophages (BMMs)	0, 25, 50, 100 nM	5 days	To evaluate the effect of Pri on F-actin ring formation, results showed Pri reduced the size and number of F-actin rings in a dose-dependent manner	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
U937 cells	10 µM	5 minutes	To assess the effect of Pristimerin on 2-AG uptake and degradation. Results showed that 10 μM Pristimerin increased intracellular [3H]-2-AG accumulation by 125% and inhibited [3H]-glycerol formation by 25%.	Br J Pharmacol. 2012 Dec;167(8):1596-608
Bone marrow macrophages (BMMs)	0.3125, 0.625, 1.25 µM	6 days	To evaluate the inhibitory effect of PRI on RANKL-induced osteoclastogenesis. Results showed that PRI dose-dependently inhibited the formation of TRAP-positive multinucleated osteoclasts, with 1.25 μM PRI treatment group predominantly showing TRAP-positive mononuclear cells.	Drug Des Devel Ther. 2021 Jan 7;15:61-74
U373 cells	4-16 µM	6 hours	To evaluate the effect of Pristimerin on U373 cell apoptosis. Results showed that Pristimerin at 4-16 μM significantly induced cell apoptosis.	Biosci Rep. 2019 May 14;39(5):BSR20182389
32D-Bcr-Abl-T315I cells	387 nM (IC50)	72 hours	Inhibited growth and induced apoptosis	Mol Cancer. 2010 May 19;9:112
32D-Bcr-Abl cells	242 nM (IC50)	72 hours	Inhibited growth and induced apoptosis	Mol Cancer. 2010 May 19;9:112
K562 cells	450 nM (IC50)	72 hours	Inhibited growth and induced apoptosis	Mol Cancer. 2010 May 19;9:112
Bone marrow-derived macrophages (BMMs)	0, 5, 10, 25, 50, 75 nM	6-7 days	To evaluate the effect of Pristimerin on osteoclast formation, results showed that Pristimerin significantly inhibited RANKL-induced osteoclast differentiation.	Front Pharmacol. 2021 Jan 15;11:621110
Bone marrow-derived macrophages (BMMs)	0, 25, 50, 100 nM	7 days	To evaluate the effect of Pri on RANKL-induced osteoclast differentiation, results showed Pri reduced the number and size of TRAP-positive multinucleated osteoclasts in a dose-dependent manner	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
MiaPaCa-2 cells	0.625 to 5 µM	72 hours	Inhibited cell proliferation and induced apoptosis	Int J Oncol. 2014 May;44(5):1707-15.
Bone marrow-derived macrophages (BMMs)	100 nM	Different time stages (D0-D2, D2-D4, D4-D6, D0-D6)	To evaluate the effect of Pri on osteoclast differentiation at different time stages, results showed Pri significantly inhibited osteoclastogenesis at the mid-stage (D2-D4)	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203

BALB/c nude mice	NCI-H1299 xenograft model	Intraperitoneal injection	0.2, 0.4 mg/kg	Every two days for a total of 16 days	To evaluate the inhibitory effect of Pristimerin on tumor growth and angiogenesis	Cell Death Dis. 2020 Apr 14;11(4):232
Male Swiss albino mice	Autoimmune hepatitis model	Intravenous injection	0.4 and 0.8 mg/kg	5 consecutive days	To evaluate the ability of Pris to protect against autoimmune hepatitis (AIH). Results showed that Pris pretreatment significantly ameliorated Con A-induced hepatic damage, reduced serum indices of hepatic damage (ALT, AST, ALP, and LDH), improved liver histopathology, decreased neutrophil infiltration and CD4+T-cell infiltration in hepatic tissue, enhanced antioxidant capacity, inhibited NF-κB activation and inflammatory cytokine release, and reduced hepatocyte apoptosis.	Front Pharmacol. 2018 Mar 28;9:292
Nude mice	MDA-MB-231 xenograft model	Intraperitoneal injection	0.5 mg/kg	Daily for 14 days	Pristimerin significantly suppressed tumor volume and weight, increased expression of cleaved caspase-3, LC-3 II, and phosphorylation-JNK	Cell Death Discov. 2019 Aug 5;5:125
BALB/c mice	Subcutaneous xenograft tumor model	Intraperitoneal injection	1 mg/kg	Every other day for a total of 7 times	To investigate the effect of pristimerin on TNBC growth in vivo, results showed that pristimerin effectively hindered the growth of TNBC, with no significant toxic side effects observed.	Adv Sci (Weinh). 2025 Mar;12(10):e2413174
C57BL/6 mice	Ovariectomized (OVX) osteoporosis model	Intraperitoneal injection	1 mg/kg	5 days per week for 8 weeks	To evaluate the protective effect of Pristimerin on osteoporosis, results showed that Pristimerin significantly ameliorated ovariectomy-induced bone loss and reduced serum inflammatory factor levels.	Front Pharmacol. 2021 Jan 15;11:621110
BALB/C nude mice	MDA-MB-231 xenograft model	Oral gavage	1 mg/kg	Every 2 days for 6 weeks	Pristimerin significantly inhibited tumor growth and reversed EMT by downregulating integrin b3 expression.	Biomed J. 2021 Dec;44(6 Suppl 1):S84-S92
Lewis rats	Adjuvant arthritis (AA)	Intraperitoneal injection	1 mg/kg	Once daily for 5 days	To evaluate the therapeutic effect of Pristimerin on arthritis. Results showed Pristimerin significantly reduced arthritis inflammation and joint damage, decreased pro-inflammatory cytokines (IL-6, IL-17, IL-18, IL-23) expression, and increased immunomodulatory cytokine IL-10 and IFN-γ expression.	Oncol Rep. 2015 Jul;34(1):518-24
Lewis rats	Adjuvant arthritis (AA)	Intraperitoneal injection	1 mg/kg	Once daily for 5 days	To evaluate the therapeutic effect of Pristimerin on arthritis. Results showed Pristimerin significantly reduced arthritis inflammation and joint damage, decreased pro-inflammatory cytokines (IL-6, IL-17, IL-18, IL-23) expression, and increased immunomodulatory cytokine IL-10 and IFN-γ expression.	Clin Immunol. 2014 Dec;155(2):220-30
Nude mice	KBM5-T315I xenograft model	Intratumoral injection	1.0 mg/kg	Daily for 14 days	Inhibited tumor growth	Mol Cancer. 2010 May 19;9:112
C57BL/6 mice	Ovariectomy (OVX) model	Intragastric administration	10 mg/kg	Every 2 days for 2 months	To evaluate the protective effect of Pri on OVX-induced bone loss, results showed Pri significantly prevented OVX-induced reduction in bone mass and trabecular structure damage	Drug Des Devel Ther. 2020 Oct 9;14:4189-4203
Mice	Destabilization of the medial meniscus (DMM) model	Intra-articular injection	200 nmol	Once a week for four consecutive weeks	To assess the effect of Pristimerin on OA progression in vivo, results showed Pristimerin could reduce cartilage degradation and slow OA progression	Drug Des Devel Ther. 2024 Nov 27;18:5445-5459
BALB/c nude mice	Human breast cancer xenograft model	Subcutaneous injection	3 mg/kg	Every other day for 16 days	Pristimerin significantly reduced both tumor volume and tumor weight, and decreased angiogenesis in a xenograft mouse tumor model in vivo. The mean number of blood vessels in the treated group was significantly lower than in the control group.	Molecules. 2012 Jun 5;17(6):6854-68
C57BL/6 mice	Ovariectomy (OVX)-induced osteoporosis model	Intraperitoneal injection	5 mg/kg	Once every two days for 6 weeks	To evaluate the protective effect of PRI against OVX-mediated bone loss. Results showed that PRI treatment significantly improved bone parameters such as bone volume (BV/TV), trabecular number (Tb.N), bone mineral density (BMD), and reduced the number of TRAP-positive osteoclasts.	Drug Des Devel Ther. 2021 Jan 7;15:61-74
C57BL/6J mice	LPS-induced systemic inflammation model	Intraperitoneal injection	500 μg/kg	Single injection	Significantly reduced serum IL-1β and IL-18 levels	Acta Pharmacol Sin. 2021 Jun;42(6):975-986
C57BL/6 mice	Pregnancy model	Intraperitoneal injection	5μg/30g	Single dose, until day 13.5	Induced fetal resorption and placental hemorrhage	Drug Des Devel Ther. 2020 Nov 2;14:4659-4670

{[proInfo.proName]}

CAS No.: 1258-84-0

{[proInfo.proName]}

CAS No.: 1258-84-0

Alternative Products

Product Details of Pristimerin

Safety of Pristimerin

Related Pathways of Pristimerin

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed